What's Happening Now is a quick, thoughtful, real-time briefing regarding material events in the stem cell industry...definitely not the usual stream of insignificant press releases. The most current Happenings are boxed on the left-hand side of most pages on this site. Feel free to use this page to explore the archive of all past Happening items, and subscribe to the RSS feed to stay on top of the events that move the market and the industry.
Osiris Sells Off Stem Cell Business
Oct 11, 2013
As we speculated in a recent essay
, Osiris Therapeutics
(OSIR) has lost interest in its stem cell business (in favor of its wound dressing product). The company announced
the sale of its stem cell assets, including Canadian-approved cell therapy Prochymal, to Australia's Mesoblast Ltd. in a transaction worth up to $100 million including milestones...a fraction of the $500 million the company's CEO recently stated Osiris had spent developing Prochymal.
Osiris Soars on Grafix trial success
Aug 13, 2013
Shares of Osiris Therapeutics
(OSIR) shot up 139% on extremely heavy volume on news
that the diabetic foot ulcer clinical trial for Grafix (a processed viable placental tissue wound dressing) will end early due to "overwhelming efficacy." While Grafix is not a stem cell treatment itself, its success provides Osiris with much-needed leeway to decide the fate of stem cell drug, Prochymal.
ViaCyte receives another $10M infusion for diabetes development
Jul 11, 2013
Privately held ViaCyte announced
a new investment in its diabetes cell therapy program by existing investors including Johnson & Johnson, matching last year's $10M award from California's Institute for Regenerative Medicine. ViaCyte's candidate competes with that of SCSI component Osiris
, which reported less than exciting Phase 2 interim results
Osiris (OSIR) Up 9% on Presentation
Mar 19, 2013
Osiris Therapeutics (OSIR) Pleasantly Surprises
Mar 6, 2013
Osiris Therapeutics'< Previous Page
) narrower than expected loss in FY2012
was greeted with exuberance, sending the SCSI to a new high for 2013. Currently Osiris is by far the largest market-cap component of the SCSI ($307 million versus second-place BioTime's $211 million), giving it an over-sized impact on the Index.
| Next Page >